Danforth Advisors, LLC ("Danforth"), the leading provider of outsourced finance, accounting, and strategic services to life science and healthcare companies, today announced the appointment of Sarah Dekin and Stephen Hoffman to the Board of Directors. Sarah is currently the Chief Operating Officer of Hometap Equity Partners and serves as an Independent Board Director for the current Stone-Goff portfolio company The Greene Turtle. Steve is an industry veteran in life sciences and pharmaceuticals and most recently served as the Chief Executive Officer for Aerpio Pharmaceuticals.
Steve brings to Danforth significant experience as an executive, director, and investor in life sciences companies. During his tenure as CEO of Aerpio, he led the company through its transition from the OTC exchange to NASDAQ and raised more than $50 million in an oversubscribed follow-on offering. Prior to Aerpio, Steve served as a Senior Advisor to PDL Biopharma and was previously a Managing Director at Skyline Ventures and General Partner of TVM Capital. Steve has also held many board positions across a variety of life sciences companies and currently serves on the Board of Directors for Dicerna Pharmaceuticals, AcelRx Pharmaceuticals, and Palleon Pharmaceuticals.
Sarah is an experienced executive with a deep history of driving growth through product, business model, and marketing opportunities. Prior to Hometap, Sarah served as Chief Marketing Officer for Virgin Money, Zipcar, and House of Blues Entertainment. She began her career as a consultant at Bain & Company and is a graduate of Harvard Business School. In addition to her Director role at The Greene Turtle, Sarah has served as a Strategy & Growth Advisor for several companies including Locu, Envoy Global, and TrueMotion.
"We are excited to welcome Sarah and Steve to the Board of Directors," said Danforth Co-Founder and Managing Director, Gregg Beloff. "Steve's deep history in the life sciences industry and Sarah's experience scaling businesses provide an ideal mix as we look to continue building the leading strategic partner for life sciences companies."
About Danforth Advisors
Danforth offers an integrated and scalable "one-stop shop" solution for life sciences companies for all operations from the controller through CFO performing activities ranging from accounting and operational finance services to financial planning and analysis, M&A, and IPO readiness. The Company has served as a strategic and trusted thought partner to over 300 clients across all stages of a company's life cycle, from inception to exit. Danforth employs a deep team of consultants who are experienced finance and accounting professionals with a background in life sciences. In addition to core finance services, Danforth recently added Clinical Outsourcing Management and Risk/Compliance services to help customers address their needs as their businesses grow. The Company is headquartered in Waltham, MA with additional offices in New York, Pennsylvania, Colorado, and Texas.
1. This release is for informational purposes only and does not constitute, or form part of, an offer to purchase or issue interests in any security or investment product. No assurance can be given that any investment managed by Stone-Goff will be able to implement its investment strategy or achieve its investment objectives.
2. This release contains statements that may be considered testimonials or endorsements. While no compensation arrangement exists between Stone-Goff and any outside parties in connection with any testimonial or endorsement made herein, those making statements could be considered to have an economic interest in the success of Stone-Goff, a particular investment, or portfolio holding.
3. Past performance is not indicative of future results. Stone-Goff does not make any representation or warranty, express or implied, regarding future performance of any investment vehicle, particular investment or portfolio holding.
